Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.
Abstract: Disclosed are a crystal form of a compound (1S,2S)-2-fluoro-N-(2-(2-(4-((R)-(5-methyl-2H-tetrazol-2-yl)(phenyl)methyl)piperidine-1-formyl)pyridin-4-yl)benzo[d]oxazol-5-yl)cyclopropyl-1-carboxamide having a structure of formula (A), a preparation method for the crystal form, and a use of the crystal form in the preparation of a drug for treating and/or preventing influenza.